A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Trial Profile

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ECHELON-1
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 02 Oct 2017 According to a Seattle Genetics media release, this trial received European Medicines Agency (EMA) scientific advice.
    • 02 Oct 2017 According to a Seattle Genetics media release, the company intend to submit a supplemental Biologics License Application to the FDA before the end of 2017.
    • 02 Oct 2017 Based on the data from this trial, the U.S. FDA has granted Breakthrough Therapy Designation to ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma, according to a Seattle Genetics media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top